A Phase 2 interventional study of Herpes Zoster vaccine GSK1437173A Low Dose and Herpes Zoster vaccine GSK1437173A Medium Dose in Herpes Zoster, sponsored by GlaxoSmithKline. Completed at 11 sites in 4 countries. Open to participants aged 60 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-03-15.
Sponsored by GlaxoSmithKline · Phase 2, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 44 studies in Herpes Zoster by GlaxoSmithKline — 3 open to participants now, 5 under way, 1 of them phase 3. Herpes Zoster · GlaxoSmithKline.
Among the 44 studies in Herpes Zoster by GlaxoSmithKline, this one is the 15th largest by enrollment of the 37 interventional ones that give a count, is one of 3 that started in 2007, is one of 8 in phase 2, and was the 2nd registered.
299 studies on the registry are indexed under Herpes Zoster; 55 are open to participants now.
Browse Herpes Zoster studies →3 of the 44 studies in Herpes Zoster by GlaxoSmithKline are open now, in 7 countries. Recruiting first, the newest first:
GlaxoSmithKline · Sites in Finland
Ages 76+ · Healthy volunteers
GlaxoSmithKline · Sites in Belgium, France, Italy and 3 more countries
Ages 1–17
GlaxoSmithKline
Ages 50+
By country, each count listing its studies:
Of the 37 Herpes Zoster studies recruiting now, 26 (70%) set no upper age limit and 6 (16%) stop at 75 or younger; 3 take children under 18; 13 take healthy volunteers.
This study: 60 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
44 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 9 · Phase 3 25 · Phase 4 2
First in 2007; this study’s year is marked. 3 started in 2007.
This study's enrollment of 715 is above the median of 160 across 247 interventional studies indexed under Herpes Zoster.
Median enrollment 450 across the 37 interventional studies, 448 across the 7 observational. Of the 39 that completed or were terminated, 34 (87%) have results posted.
This tab as a report to print or save as PDF → With an account.
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
1 of the studies in Herpes Zoster by GlaxoSmithKline that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05371080Phase 3GlaxoSmithKlineA Study on the Long-term Efficacy, Safety and Persistence of Immune Response of a Vaccine Against Herpes Zoster in Older Adults | 2027-08-23 |
Add it to your calendar (.ics) → With an account.
Among the 44 studies in Herpes Zoster by GlaxoSmithKline, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Based on the results of a previous clinical PhaseI/II study, GSK1437173A is the lead GSK candidate Herpes Zoster (HZ) vaccine to prevent episodes of HZ (shingles). This phase II study will be subdivided into a primary study (108494) and three extension studies (108516, 108518 \& 108520), consisting of one additional visit each at months 12, 24 and 36, respectively, from the first visit of the Zoster-003 primary study onwards. The aim of the primary 108494 study is to evaluate the immunogenicity \& safety of different dosages of the GSK1437173A vaccine in healthy elderly population. The study population will be stratified by age. The primary objective of this trial is to select the best dosage of GSK1437173A. The aim of the extension studies is to evaluate the persistence of the immune response induced by the candidate HZ vaccine during a long term period.
No new subjects will be enrolled during the extension phases of the study.
The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Healthy male or female subjects aged 60 years or older, who received 2 doses of herpes zoster subunit vaccine (GSK1437173A) low dose (LD) formulation, according to a 0, 2-month schedule. The vaccine was administrated by intramuscular injection (IM) in the upper deltoid site of the left arm.
Biological: Herpes Zoster vaccine GSK1437173A Low Dose
Healthy male or female subjects aged 60 years or older, who received 2 doses of herpes zoster subunit vaccine (GSK1437173A) medium dose (MD) formulation, according to a 0, 2-month schedule. The vaccine was administrated by (IM) in the upper deltoid site of the left arm.
Biological: Herpes Zoster vaccine GSK1437173A Medium Dose
Healthy male or female subjects aged 60 years or older, who received 2 doses of herpes zoster subunit vaccine (GSK1437173A) high dose (HD) formulation, according to a 0, 2-month schedule. The vaccine was administrated by (IM) in the upper deltoid site of the left arm.
Biological: Herpes Zoster vaccine GSK1437173A High Dose
Healthy male or female subjects aged 60 years or older, who received a 1st dose of saline solution and a 2nd dose of GSK1437173A high dose (HD) formulation, according to a 0, 2-month schedule. The vaccine was administrated by (IM) in the upper deltoid site of the left arm.
Biological: Herpes Zoster vaccine GSK1437173A High Dose · Biological: Placebo
Healthy male or female subjects aged 60 years or older, who received 2 doses of GSK1437173A modified formulation vaccine reconstituted with saline solution, according to a 0, 2-month schedule. The vaccine was administrated by (IM) in the upper deltoid site of the left arm.
Biological: Herpes Zoster vaccine GSK1437173A Modified
Single or two-dose intramuscular injection.
Single or two-dose intramuscular injection.
Single or two-dose intramuscular injection.
Single or two-dose intramuscular injection.
Single intramuscular injection
Frequency of Glycoprotein E (gE)-Specific Cluster of Differentiation (CD4) T-cells Expressing at Least Two Different Activation Markers
Among the activation markers expressed were interleukin-2 \[IL-2\] and/or interferon-gamma \[IFN-γ\] and/or tumour necrosis factor-alpha \[TNF-α\] and/or cluster of differentiation 40-ligand \[CD40-L\]. Analysis of cytokines expression was done by means of in vitro flow cytometry using intracellular cytokine staining (ICS) in subjects aged 70 or higher (≥).
Time frame: One month after the second vaccination (Month 3)
Frequency Odds Ratio of gE-specific CD4 T-cells Expressing at Least Two Different Activation Markers
Among the activation markers expressed were interleukin-2 \[IL-2\] and/or interferon-gamma \[IFN-γ\] and/or tumour necrosis factor-alpha \[TNF-α\] and/or cluster of differentiation 40-ligand \[CD40-L\]. Analysis of cytokines expression was done by means of in vitro flow cytometry using intracellular cytokine staining (ICS) in subjects ≥ 70 years old. The odds-ratios are calculated using the the frequency of CD4 secreting cytokines, upon in vitro stimulation with the specific antigen, at the numerator and the frequency of the CD4 secreting cytokines with the medium only (background level) at the denominator. The odds-ratios represent the fold-change in the specific response compared to the background level.
Time frame: One month after the second vaccination (Month 3)
Frequency of gE-specific CD4 T-cells Expressing at Least Two Different Activation Markers
Among the activation markers expressed were interleukin-2 \[IL-2\] and/or interferon-gamma \[IFN-γ\] and/or tumour necrosis factor-alpha \[TNF-α\] and/or cluster of differentiation 40-ligand \[CD40-L\]. Analysis of cytokines expression was done by means of in vitro flow cytometry using intracellular cytokine staining (ICS) in subjects ≥ 70 years old.
Time frame: One month after the second vaccination (Month 3)
Frequency of gE-specific CD4 T-cells Expressing at Least Two Different Activation Markers
Among the activation markers expressed were interleukin-2 \[IL-2\] and/or interferon-gamma \[IFN-γ\] and/or tumour necrosis factor-alpha \[TNF-α\] and/or cluster of differentiation 40-ligand \[CD40-L\]. Analysis of cytokines expression was done by means of in vitro flow cytometry using intracellular cytokine staining (ICS) in subjects 60 to 69 years (60-69y) and ≥ 70 years (+70y) old.
Time frame: At pre-vaccination (Day 0), one month after the first vaccination (Month 2) and second vaccination (Month 3)
Frequency of gE-specific CD4 T-cells Expressing IFN-γ and at Least Another Activation Marker
Among other activation markers expressed were interleukin-2 \[IL-2\] or tumour necrosis factor-alpha \[TNF-α\] or cluster of differentiation 40-ligand \[CD40-L\]. Analysis of cytokines expression was done by means of in vitro flow cytometry using intracellular cytokine staining (ICS).
Time frame: At pre-vaccination (Day 0), one month after the first vaccination (Month 2) and second vaccination (Month 3)
Frequency of gE-specific CD4 T-cells Expressing IL-2 and at Least Another Activation Marker
Among other activation markers expressed were interferon-gamma \[IFN-γ\] or tumour necrosis factor-alpha \[TNF-α\] or cluster of differentiation 40-ligand \[CD40-L\]. Analysis of cytokines expression was done by means of in vitro flow cytometry using intracellular cytokine staining (ICS).
Time frame: At pre-vaccination (Day 0), one month after the first vaccination (Month 2) and second vaccination (Month 3)
Frequency of gE-specific CD4 T-cells Expressing TNF-α and at Least Another Activation Marker
Among other activation markers expressed were interleukin-2 \[IL-2\] or interferon-gamma \[IFN-γ\] or cluster of differentiation 40-ligand \[CD40-L\]. Analysis of cytokines expression was done by means of in vitro flow cytometry using intracellular cytokine staining (ICS).
Time frame: At pre-vaccination (Day 0), one month after the first vaccination (Month 2) and second vaccination (Month 3)
Frequency of gE-specific CD4 T-cells Expressing CD40L and at Least Another Activation Marker
Among other activation markers expressed were interleukin-2 \[IL-2\] or interferon-gamma \[IFN-γ\] or tumour necrosis factor-alpha \[TNF-α\] . Analysis of cytokines expression was done by means of in vitro flow cytometry using intracellular cytokine staining (ICS).
Time frame: At pre-vaccination (Day 0), one month after the first vaccination (Month 2) and second vaccination (Month 3)
Frequency of gE-specific CD8 T-cells Expressing at Least Two Different Activation Markers
Among the activation markers expressed were interleukin-2 \[IL-2\] and/or interferon-gamma \[IFN-γ\] and/or tumour necrosis factor-alpha \[TNF-α\] and/or cluster of differentiation 40-ligand \[CD40-L\]. Analysis of cytokines expression was done by means of in vitro flow cytometry using intracellular cytokine staining (ICS).
Time frame: At pre-vaccination (Day 0), one month after the first vaccination (Month 2) and second vaccination (Month 3)
Frequency of gE-specific CD8 T-cells Expressing IFN-γ and at Least Another Activation Marker
Among other activation markers expressed were interleukin-2 \[IL-2\] or tumour necrosis factor-alpha \[TNF-α\] or cluster of differentiation 40-ligand \[CD40-L\]. Analysis of cytokines expression was done by means of in vitro flow cytometry using intracellular cytokine staining (ICS).
Time frame: At pre-vaccination (Day 0), one month after the first vaccination (Month 2) and second vaccination (Month 3)
Frequency of gE-specific CD8 T-cells Expressing IL-2 and at Least Another Activation Marker
Among other activation markers expressed were interferon-gamma \[IFN-γ\] or tumour necrosis factor-alpha \[TNF-α\] or cluster of differentiation 40-ligand \[CD40-L\]. Analysis of cytokines expression was done by means of in vitro flow cytometry using intracellular cytokine staining (ICS).
Time frame: At pre-vaccination (Day 0), one month after the first vaccination (Month 2) and second vaccination (Month 3)
Frequency of gE-specific CD8 T-cells Expressing TNF-α and at Least Another Activation Marker
Among other activation markers expressed were interleukin-2 \[IL-2\] or interferon-gamma \[IFN-γ\] or cluster of differentiation 40-ligand \[CD40-L\]. Analysis of cytokines expression was done by means of in vitro flow cytometry using intracellular cytokine staining (ICS).
Time frame: At pre-vaccination (Day 0), one month after the first vaccination (Month 2) and second vaccination (Month 3)
Frequency of gE-specific CD8 T-cells Expressing CD40L and at Least Another Activation Marker
Among other activation markers expressed were interleukin-2 \[IL-2\] or interferon-gamma \[IFN-γ\] or tumour necrosis factor-alpha \[TNF-α\]. Analysis of cytokines expression was done by means of in vitro flow cytometry using intracellular cytokine staining (ICS).
Time frame: At pre-vaccination (Day 0), one month after the first vaccination (Month 2) and second vaccination (Month 3)
Anti-gE Specific Antibody Concentrations
Concentrations were presented as geometric mean concentrations (GMCs) and expressed in enzyme-linked immunosorbent assay (ELISA) units per milliliter (EL.U/mL).
Time frame: At pre-vaccination (Day 0), one month after the first vaccination (Month 2) and second vaccination (Month 3)
Anti-varicella Zoster Virus (VZV) Specific Antibody Concentrations
Concentrations were presented as geometric mean concentrations (GMCs) and expressed in milli-international units per milliliter (mIU/mL), as assessed by ELISA.
Time frame: At pre-vaccination (Day 0), one month after the first vaccination (Month 2) and second vaccination (Month 3)
Frequency of gE-specific CD4/CD8 T-cells Expressing at Least Two Different Activation Markers
Among the activation markers expressed were interleukin-2 \[IL-2\] and/or interferon-gamma \[IFN-γ\] and/or tumour necrosis factor-alpha \[TNF-α\] and/or cluster of differentiation 40-ligand \[CD40-L\]. Analysis of cytokines expression was done by means of in vitro flow cytometry using intracellular cytokine staining (ICS). Month 12, 24 and 36 CMI analyses on CD8+ T cells were not performed as no detectable CD8 T+ cell response was measured to any of the vaccine formulations in the primary (108494) study.
Time frame: At Months 12, 24 and 36
Frequency of gE-specific CD4/CD8 T-cells Expressing IFN-γ and at Least Another Activation Marker
Among other activation markers expressed were interleukin-2 \[IL-2\] or tumour necrosis factor-alpha \[TNF-α\] or cluster of differentiation 40-ligand \[CD40-L\]. Analysis of cytokines expression was done by means of in vitro flow cytometry using intracellular cytokine staining (ICS). Month 12, 24 and 36 CMI analyses on CD8+ T cells were not performed as no detectable CD8 T+ cell response was measured to any of the vaccine formulations in the primary (108494) study.
Time frame: At Months 12, 24 and 36
Frequency of gE-specific CD4/CD8 T-cells Expressing IL-2 and at Least Another Activation Marker
Among other activation markers expressed were interferon-gamma \[IFN-γ\] or tumour necrosis factor-alpha \[TNF-α\] or cluster of differentiation 40-ligand \[CD40-L\]. Analysis of cytokines expression was done by means of in vitro flow cytometry using intracellular cytokine staining (ICS). Month 12, 24 and 36 CMI analyses on CD8+ T cells were not performed as no detectable CD8 T+ cell response was measured to any of the vaccine formulations in the primary (108494) study.
Time frame: At Months 12, 24 and 36
Frequency of gE-specific CD4/CD8 T-cells Expressing TNFα and at Least Another Activation Marker
Among other activation markers expressed were interleukin-2 \[IL-2\] or interferon-gamma \[IFN-γ\] or cluster of differentiation 40-ligand \[CD40-L\]. Analysis of cytokines expression was done by means of in vitro flow cytometry using intracellular cytokine staining (ICS). Month 12, 24 and 36 CMI analyses on CD8+ T cells were not performed as no detectable CD8 T+ cell response was measured to any of the vaccine formulations in the primary (108494) study.
Time frame: At Month 12, 24 and 36
Frequency of gE-specific CD4/CD8 T-cells Expressing CD40L and at Least Another Activation Marker
Among other activation markers expressed were interleukin-2 \[IL-2\] or interferon-gamma \[IFN-γ\] or tumour necrosis factor-alpha \[TNF-α\] . Analysis of cytokines expression was done by means of in vitro flow cytometry using intracellular cytokine staining (ICS). Month 12, 24 and 36 CMI analyses on CD8+ T cells were not performed as no detectable CD8 T+ cell response was measured to any of the vaccine formulations in the primary (108494) study.
Time frame: At Month 12, 24 and 36
Anti-gE Specific Antibody Concentrations
Concentrations were presented as geometric mean concentrations (GMCs) and expressed in enzyme-linked immunosorbent assay (ELISA) units per milliliter (EL.U/mL).
Time frame: At Months 12, 24 and 36
Anti-varicella Zoster Virus (VZV) Specific Antibody Concentrations
Concentrations were presented as geometric mean concentrations (GMCs) and expressed in milli-international units per milliliter (mIU/mL).
Time frame: At Months 12, 24 and 36
Frequency of VZV-specific Memory B-cells in a Subset of Subjects
Memory B cells specific to the gE antigen, as assessed by the enzyme-linked immunosorbent spot (ELISPOT) method, were expressed as a frequency of the specific memory B-cells per million memory B-cells. Results were tabulated for subjects aged 70 years and older.
Time frame: At pre-vaccination (Day 0) and at Month 3
Number of Subjects With Different Biochemical and Haematological Levels
Among biochemical and haematological parameters assessed were albumin \[ALB\], alanine aminotransferase \[ALT\], aspartate aminotransferase \[AST\], basophils \[BAS\], calcium \[CAL\], eosinophils \[EOS\], fibrinogen \[FIB\], haematocrit \[HEM\], hemoglobin \[Hgb\], leucocytes \[LEU\], lymphocytes \[LYM\], lactate dehydrogenate \[LDH\], monocytes \[MON\], neutrophils \[NEU\], partial thromboplastin time \[PTPT\], platelets \[PLA\], pro thrombin time \[PTT\], red blood cells \[RBC\], serum creatinine \[SCREA\], total protein \[TP\]. Levels of haematological/biochemical parameters assessed in terms of normal laboratory values were - unknown, below, within and above.
Time frame: At Day 0, Month 2 and Month 3
Number of German Subjects With Different Biochemical and Haematological Levels
Among biochemical and haematological parameters assessed were albumin \[ALB\], calcium \[CAL\], fibrinogen \[FIB\], lactate dehydrogenase \[LDH\], partial thrombo-plastin time \[PTPT\], pro thrombin time \[PTT\], total protein \[TP\]. Levels of haematological/biochemical parameters assessed in terms of normal laboratory values were - below, within, above and missing, as compared to the pre-vaccination status (below, within, above or missing). Values for electrophoresis (globulins and albumin/globulin ratio) were not displayed.
Time frame: At one week post-vaccination 1 (Month 0)
Number of German Subjects With Different Biochemical and Haematological Levels
Among biochemical and haematological parameters assessed were albumin \[ALB\], calcium \[CAL\], fibrinogen \[FIB\], lactate dehydrogenase \[LDH\], partial thrombo-plastin time \[PTPT\], pro thrombin time \[PTT\], total protein \[TP\]. Levels of haematological/biochemical parameters assessed in terms of normal laboratory values were - below, within, above and missing, as compared to the pre-vaccination status (below, within, above or missing). Values for electrophoresis (globulins and albumin/globulin ratio) were not displayed.
Time frame: At one week post-vaccination 2 (Month 2)
Number of Subjects With Any and Grade 3 Solicited Local Symptoms
Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 pain = pain that prevented normal activity. Grade 3 redness/swelling = redness/swelling spreading beyond 100 millimeters (mm) of injection site.
Time frame: During the 7-day (Days 0-6) post-vaccination period following each dose and across doses
Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms
Assessed solicited general symptoms were arthralgia, fatigue, fever \[defined as oral temperature equal to or above (≥) 37.5 degrees Celsius (°C)\], headache and myalgia. Any = occurrence of the symptom regardless of intensity grade. Grade 3 symptom = symptom that prevented normal activity. Grade 3 fever = fever \> 39.0 °C. Related = symptom assessed by the investigator as related to the vaccination.
Time frame: During the 7-day (Days 0-6) post-vaccination period following each dose and across doses
Number of Subjects With Occurrence of Clinically Diagnosed Herpes Zoster (HZ) Episodes
Clinically diagnosed episodes included rash that was assessed by hives, idiopathic thrombocytopenic purpura, petechiae.
Time frame: From Month 0 to Month 3
Number of Subjects With Occurrence of Clinically Diagnosed HZ Episodes
Clinically diagnosed episodes included rash that was assessed by hives, idiopathic thrombocytopenic purpura, petechiae.
Time frame: From Month 3 up to Month 36
Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs)
An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. Grade 3 AE = an AE which prevented normal, everyday activities. Related = AE assessed by the investigator as related to the vaccination.
Time frame: During the 30-day (Days 0-29) post-vaccination period
Number of Subjects With Serious Adverse Events (SAEs)
Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.
Time frame: From Month 0 to Month 3
Number of Subjects With Serious Adverse Events (SAEs)
Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.
Time frame: From Month 3 to Month 12
| Milestone | GSK1437173A _LD Group | GSK1437173A _MD Group | GSK1437173A _HD Group | Placebo + GSK1437173A _HD Group | GSK1437173A_MODIFIED Group |
|---|---|---|---|---|---|
| Started | 164 | 166 | 165 | 165 | 54 |
| Completed | 161 | 164 | 161 | 164 | 51 |
| Not completed | 3 | 2 | 4 | 1 | 3 |
| Withdrew: Serious adverse event | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Adverse event | 0 | 1 | 1 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 2 |
| Withdrew: Protocol violation | 1 | 0 | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 2 | 1 | 1 | 1 | 1 |
| Milestone | GSK1437173A _LD Group | GSK1437173A _MD Group | GSK1437173A _HD Group | Placebo + GSK1437173A _HD Group | GSK1437173A_MODIFIED Group |
|---|---|---|---|---|---|
| Started | 156 | 159 | 159 | 161 | 50 |
| Completed | 156 | 159 | 159 | 161 | 50 |
| Not completed | 0 | 0 | 0 | 0 | 0 |
| Milestone | GSK1437173A _LD Group | GSK1437173A _MD Group | GSK1437173A _HD Group | Placebo + GSK1437173A _HD Group | GSK1437173A_MODIFIED Group |
|---|---|---|---|---|---|
| Started | 150 | 155 | 154 | 157 | 49 |
| Completed | 150 | 155 | 154 | 157 | 49 |
| Not completed | 0 | 0 | 0 | 0 | 0 |
| Milestone | GSK1437173A _LD Group | GSK1437173A _MD Group | GSK1437173A _HD Group | Placebo + GSK1437173A _HD Group | GSK1437173A_MODIFIED Group |
|---|---|---|---|---|---|
| Started | 147 | 147 | 150 | 155 | 47 |
| Completed | 147 | 147 | 150 | 155 | 47 |
| Not completed | 0 | 0 | 0 | 0 | 0 |
Among the activation markers expressed were interleukin-2 \[IL-2\] and/or interferon-gamma \[IFN-γ\] and/or tumour necrosis factor-alpha \[TNF-α\] and/or cluster of differentiation 40-ligand \[CD40-L\]. Analysis of cytokines expression was done by means of in vitro flow cytometry using intracellular cytokine staining (ICS) in subjects aged 70 or higher (≥).
| T-cells/million cells | GSK1437173A _LD Group | GSK1437173A _MD Group | GSK1437173A _HD Group | Placebo + GSK1437173A _HD Group | GSK1437173A_MODIFIED Group |
|---|---|---|---|---|---|
| Frequency of Glycoprotein E (gE)-Specific Cluster of Differentiation (CD4) T-cells Expressing at Least Two Different Activation Markers | 1801.23 (907.17 to 2930.71) | 1722.83 (1172.96 to 3229.73) | 1778.48 (1154.88 to 3407.91) | 491.03 (320.65 to 768.17) | 388.49 (208.57 to 610.66) |
Among the activation markers expressed were interleukin-2 \[IL-2\] and/or interferon-gamma \[IFN-γ\] and/or tumour necrosis factor-alpha \[TNF-α\] and/or cluster of differentiation 40-ligand \[CD40-L\]. Analysis of cytokines expression was done by means of in vitro flow cytometry using intracellular cytokine staining (ICS) in subjects ≥ 70 years old. The odds-ratios are calculated using the the frequency of CD4 secreting cytokines, upon in vitro stimulation with the specific antigen, at the numerator and the frequency of the CD4 secreting cytokines with the medium only (background level) at the denominator. The odds-ratios represent the fold-change in the specific response compared to the background level.
| Fold Change | GSK1437173A _LD Group | GSK1437173A _MD Group | GSK1437173A _HD Group | Placebo + GSK1437173A _HD Group | GSK1437173A_MODIFIED Group |
|---|---|---|---|---|---|
| Frequency Odds Ratio of gE-specific CD4 T-cells Expressing at Least Two Different Activation Markers | 12.83 ± 13.13 | 15.00 ± 15.86 | 21.53 ± 71.96 | 5.92 ± 9.56 | 4.05 ± 3.20 |
Among the activation markers expressed were interleukin-2 \[IL-2\] and/or interferon-gamma \[IFN-γ\] and/or tumour necrosis factor-alpha \[TNF-α\] and/or cluster of differentiation 40-ligand \[CD40-L\]. Analysis of cytokines expression was done by means of in vitro flow cytometry using intracellular cytokine staining (ICS) in subjects ≥ 70 years old.
| T-cells/million cells | GSK1437173A _LD Group | GSK1437173A _MD Group | GSK1437173A _HD Group | Placebo + GSK1437173A _HD Group | GSK1437173A_MODIFIED Group |
|---|---|---|---|---|---|
| Frequency of gE-specific CD4 T-cells Expressing at Least Two Different Activation Markers | 2269.84 ± 1934.55 | 2441.95 ± 2055.11 | 2449.90 ± 1808.00 | 681.73 ± 665.17 | 512.55 ± 463.35 |
Among the activation markers expressed were interleukin-2 \[IL-2\] and/or interferon-gamma \[IFN-γ\] and/or tumour necrosis factor-alpha \[TNF-α\] and/or cluster of differentiation 40-ligand \[CD40-L\]. Analysis of cytokines expression was done by means of in vitro flow cytometry using intracellular cytokine staining (ICS) in subjects 60 to 69 years (60-69y) and ≥ 70 years (+70y) old.
| T-cells/million cells | GSK1437173A _LD Group | GSK1437173A _MD Group | GSK1437173A _HD Group | Placebo + GSK1437173A _HD Group | GSK1437173A_MODIFIED Group |
|---|---|---|---|---|---|
| CD4-All Doubles, Day 0 | 194.47 ± 214.96 | 225.47 ± 370.67 | 201.17 ± 230.96 | 203.70 ± 221.97 | 145.95 ± 164.57 |
| CD4-All Doubles, Month 2 | 459.01 ± 401.25 | 482.84 ± 425.73 | 489.45 ± 423.52 | 173.91 ± 181.86 | 230.28 ± 250.70 |
| CD4-All Double, Month 3 | 2246.29 ± 1976.42 | 2372.07 ± 1877.43 | 2569.29 ± 2052.74 | 670.80 ± 606.93 | 550.11 ± 448.15 |
Among other activation markers expressed were interleukin-2 \[IL-2\] or tumour necrosis factor-alpha \[TNF-α\] or cluster of differentiation 40-ligand \[CD40-L\]. Analysis of cytokines expression was done by means of in vitro flow cytometry using intracellular cytokine staining (ICS).
| T-cells/million cells | GSK1437173A _LD Group | GSK1437173A _MD Group | GSK1437173A _HD Group | Placebo + GSK1437173A _HD Group | GSK1437173A_MODIFIED Group |
|---|---|---|---|---|---|
| Day 0 | 156.54 ± 199.12 | 169.01 ± 326.34 | 152.28 ± 220.50 | 157.13 ± 180.00 | 118.35 ± 125.08 |
| Month 2 | 279.39 ± 343.61 | 279.20 ± 336.29 | 292.15 ± 345.65 | 124.05 ± 151.42 | 168.34 ± 213.83 |
| Month 3 | 1179.29 ± 1021.14 | 1296.04 ± 1132.18 | 1417.40 ± 1303.60 | 363.23 ± 364.74 | 341.36 ± 313.79 |
Among other activation markers expressed were interferon-gamma \[IFN-γ\] or tumour necrosis factor-alpha \[TNF-α\] or cluster of differentiation 40-ligand \[CD40-L\]. Analysis of cytokines expression was done by means of in vitro flow cytometry using intracellular cytokine staining (ICS).
| T-cells/million cells | GSK1437173A _LD Group | GSK1437173A _MD Group | GSK1437173A _HD Group | Placebo + GSK1437173A _HD Group | GSK1437173A_MODIFIED Group |
|---|---|---|---|---|---|
| Day 0 | 171.21 ± 208.49 | 191.28 ± 307.40 | 180.85 ± 193.48 | 172.41 ± 184.32 | 125.22 ± 134.81 |
| Month 2 | 416.12 ± 369.85 | 442.17 ± 363.10 | 438.27 ± 378.81 | 150.47 ± 160.29 | 199.34 ± 224.39 |
| Month 3 | 2077.06 ± 1860.40 | 2156.40 ± 1697.78 | 2315.84 ± 1847.24 | 597.76 ± 531.07 | 491.06 ± 396.39 |
Among other activation markers expressed were interleukin-2 \[IL-2\] or interferon-gamma \[IFN-γ\] or cluster of differentiation 40-ligand \[CD40-L\]. Analysis of cytokines expression was done by means of in vitro flow cytometry using intracellular cytokine staining (ICS).
| T-cells//million cells | GSK1437173A _LD Group | GSK1437173A _MD Group | GSK1437173A _HD Group | Placebo + GSK1437173A _HD Group | GSK1437173A_MODIFIED Group |
|---|---|---|---|---|---|
| Day 0 | 97.28 ± 137.06 | 121.05 ± 296.79 | 116.91 ± 173.65 | 110.66 ± 162.02 | 81.40 ± 107.44 |
| Month 2 | 251.94 ± 277.71 | 256.15 ± 304.91 | 263.39 ± 284.96 | 95.84 ± 125.15 | 120.73 ± 148.24 |
| Month 3 | 1317.39 ± 1304.53 | 1282.96 ± 1183.69 | 1389.62 ± 1231.76 | 350.23 ± 380.60 | 252.86 ± 253.55 |
Among other activation markers expressed were interleukin-2 \[IL-2\] or interferon-gamma \[IFN-γ\] or tumour necrosis factor-alpha \[TNF-α\] . Analysis of cytokines expression was done by means of in vitro flow cytometry using intracellular cytokine staining (ICS).
| T-cells/million cells | GSK1437173A _LD Group | GSK1437173A _MD Group | GSK1437173A _HD Group | Placebo + GSK1437173A _HD Group | GSK1437173A_MODIFIED Group |
|---|---|---|---|---|---|
| Day 0 | 142.88 ± 169.52 | 153.80 ± 214.95 | 151.37 ± 160.38 | 155.90 ± 187.47 | 111.55 ± 126.92 |
| Month 2 | 385.34 ± 348.25 | 405.95 ± 359.46 | 417.20 ± 361.59 | 132.62 ± 144.06 | 182.82 ± 195.36 |
| Month 3 | 2014.37 ± 1849.25 | 2154.81 ± 1799.64 | 2303.13 ± 1987.94 | 567.33 ± 566.48 | 433.56 ± 391.64 |
Among the activation markers expressed were interleukin-2 \[IL-2\] and/or interferon-gamma \[IFN-γ\] and/or tumour necrosis factor-alpha \[TNF-α\] and/or cluster of differentiation 40-ligand \[CD40-L\]. Analysis of cytokines expression was done by means of in vitro flow cytometry using intracellular cytokine staining (ICS).
| T-cells/million cells | GSK1437173A _LD Group | GSK1437173A _MD Group | GSK1437173A _HD Group | Placebo + GSK1437173A _HD Group | GSK1437173A_MODIFIED Group |
|---|---|---|---|---|---|
| CD8-All Doubles, Day 0 | 74.62 ± 118.02 | 98.88 ± 164.52 | 122.37 ± 221.20 | 80.54 ± 121.84 | 108.21 ± 330.11 |
| CD8-All Doubles, Month 2 | 85.29 ± 139.32 | 106.23 ± 141.63 | 86.35 ± 168.10 | 120.06 ± 221.20 | 98.97 ± 299.34 |
| CD8-All Doubles, Month 3 | 96.43 ± 155.37 | 88.77 ± 140.95 | 117.70 ± 196.09 | 112.99 ± 165.52 | 116.41 ± 450.85 |
Among other activation markers expressed were interleukin-2 \[IL-2\] or tumour necrosis factor-alpha \[TNF-α\] or cluster of differentiation 40-ligand \[CD40-L\]. Analysis of cytokines expression was done by means of in vitro flow cytometry using intracellular cytokine staining (ICS).
| T-cells/million cells | GSK1437173A _LD Group | GSK1437173A _MD Group | GSK1437173A _HD Group | Placebo + GSK1437173A _HD Group | GSK1437173A_MODIFIED Group |
|---|---|---|---|---|---|
| Day 0 | 60.35 ± 97.12 | 75.79 ± 114.55 | 106.39 ± 199.96 | 70.69 ± 121.23 | 123.99 ± 360.75 |
| Month 2 | 65.97 ± 111.02 | 106.74 ± 133.15 | 72.58 ± 92.99 | 106.02 ± 184.40 | 95.05 ± 326.45 |
| Month 3 | 88.62 ± 136.13 | 76.92 ± 123.74 | 95.01 ± 138.77 | 96.91 ± 161.10 | 125.69 ± 480.05 |
Among other activation markers expressed were interferon-gamma \[IFN-γ\] or tumour necrosis factor-alpha \[TNF-α\] or cluster of differentiation 40-ligand \[CD40-L\]. Analysis of cytokines expression was done by means of in vitro flow cytometry using intracellular cytokine staining (ICS).
| T-cells/million cells | GSK1437173A _LD Group | GSK1437173A _MD Group | GSK1437173A _HD Group | Placebo + GSK1437173A _HD Group | GSK1437173A_MODIFIED Group |
|---|---|---|---|---|---|
| Day 0 | 81.42 ± 108.62 | 83.13 ± 131.07 | 90.71 ± 140.18 | 63.56 ± 89.18 | 43.03 ± 58.88 |
| Month 2 | 61.05 ± 106.36 | 78.18 ± 92.65 | 83.07 ± 186.88 | 82.47 ± 126.08 | 68.98 ± 85.29 |
| Month 3 | 69.06 ± 97.12 | 65.08 ± 83.71 | 103.17 ± 179.57 | 82.95 ± 99.47 | 56.42 ± 120.85 |
Among other activation markers expressed were interleukin-2 \[IL-2\] or interferon-gamma \[IFN-γ\] or cluster of differentiation 40-ligand \[CD40-L\]. Analysis of cytokines expression was done by means of in vitro flow cytometry using intracellular cytokine staining (ICS).
| T-cells/million cells | GSK1437173A _LD Group | GSK1437173A _MD Group | GSK1437173A _HD Group | Placebo + GSK1437173A _HD Group | GSK1437173A_MODIFIED Group |
|---|---|---|---|---|---|
| Day 0 | 74.94 ± 113.07 | 87.33 ± 117.28 | 111.54 ± 204.36 | 81.54 ± 119.17 | 122.68 ± 362.64 |
| Month 2 | 71.42 ± 96.41 | 83.01 ± 124.50 | 75.88 ± 129.33 | 111.15 ± 217.08 | 115.82 ± 356.29 |
| Month 3 | 86.81 ± 120.39 | 76.75 ± 137.37 | 99.07 ± 139.42 | 106.97 ± 167.59 | 136.22 ± 470.58 |
Among other activation markers expressed were interleukin-2 \[IL-2\] or interferon-gamma \[IFN-γ\] or tumour necrosis factor-alpha \[TNF-α\]. Analysis of cytokines expression was done by means of in vitro flow cytometry using intracellular cytokine staining (ICS).
| T-cells/million cells | GSK1437173A _LD Group | GSK1437173A _MD Group | GSK1437173A _HD Group | Placebo + GSK1437173A _HD Group | GSK1437173A_MODIFIED Group |
|---|---|---|---|---|---|
| Day 0 | 41.35 ± 54.48 | 61.30 ± 118.43 | 56.85 ± 78.31 | 35.96 ± 69.51 | 59.94 ± 75.13 |
| Month 2 | 63.87 ± 82.02 | 66.76 ± 90.29 | 47.20 ± 64.54 | 71.20 ± 93.18 | 54.63 ± 69.92 |
| Month 3 | 69.50 ± 105.36 | 65.34 ± 64.17 | 85.57 ± 105.34 | 76.19 ± 72.44 | 33.12 ± 47.32 |
Concentrations were presented as geometric mean concentrations (GMCs) and expressed in enzyme-linked immunosorbent assay (ELISA) units per milliliter (EL.U/mL).
| EL.U/mL | GSK1437173A _LD Group | GSK1437173A _MD Group | GSK1437173A _HD Group | Placebo + GSK1437173A _HD Group | GSK1437173A_MODIFIED Group |
|---|---|---|---|---|---|
| Anti-gE, Day 0 | 351.6 (306.2 to 403.8) | 312.8 (268.1 to 365.0) | 416.1 (355.0 to 487.7) | 337.2 (285.8 to 397.7) | 323.7 (245.2 to 427.3) |
| Anti-gE, Month 2 | 3667.6 (3158.6 to 4258.7) | 4139.4 (3443.8 to 4975.4) | 5485.6 (4657.2 to 6461.3) | 361.5 (304.6 to 429.0) | 2148.9 (1461.8 to 3158.9) |
| Anti-gE, Month 3 | 9315.3 (8283.2 to 10476.1) | 12898.0 (11681.2 to 14241.6) | 15626.5 (14030.3 to 17404.3) | 6287.2 (5372.0 to 7358.3) | 4298.3 (3220.0 to 5737.7) |
Concentrations were presented as geometric mean concentrations (GMCs) and expressed in milli-international units per milliliter (mIU/mL), as assessed by ELISA.
| mIU/mL | GSK1437173A _LD Group | GSK1437173A _MD Group | GSK1437173A _HD Group | Placebo + GSK1437173A _HD Group | GSK1437173A_MODIFIED Group |
|---|---|---|---|---|---|
| Anti-VZV, Day 0 | 1334.9 (1181.9 to 1507.7) | 1212.0 (1063.9 to 1380.7) | 1510.7 (1336.4 to 1707.7) | 1356.3 (1184.9 to 1552.6) | 1422.5 (1153.4 to 1754.5) |
| Anti-VZV, Month 2 | 4408.1 (3847.7 to 5050.1) | 5131.9 (4469.8 to 5892.0) | 6511.7 (5723.1 to 7409.0) | 1341.6 (1177.7 to 1528.3) | 3481.2 (2756.0 to 4397.3) |
| Anti-VZV, Month 3 | 8821.6 (7959.3 to 9777.4) | 11451.0 (10507.9 to 12478.7) | 14143.5 (12876.9 to 15534.7) | 6432.2 (5591.8 to 7398.9) | 5357.6 (4297.3 to 6679.4) |
Among the activation markers expressed were interleukin-2 \[IL-2\] and/or interferon-gamma \[IFN-γ\] and/or tumour necrosis factor-alpha \[TNF-α\] and/or cluster of differentiation 40-ligand \[CD40-L\]. Analysis of cytokines expression was done by means of in vitro flow cytometry using intracellular cytokine staining (ICS). Month 12, 24 and 36 CMI analyses on CD8+ T cells were not performed as no detectable CD8 T+ cell response was measured to any of the vaccine formulations in the primary (108494) study.
| T-cells/million cells | GSK1437173A _LD Group | GSK1437173A _MD Group | GSK1437173A _HD Group | Placebo + GSK1437173A _HD Group | GSK1437173A_MODIFIED Group |
|---|---|---|---|---|---|
| CD4-All Doubles, Month 12 | 1135.8 ± 936.0 | 1275.5 ± 1195.4 | 1274.0 ± 995.0 | 340.4 ± 296.8 | 274.5 ± 217.3 |
| CD4-All Doubles, Month 24 | 1004.1 ± 838.8 | 1195.5 ± 1375.5 | 1079.9 ± 948.0 | 244.1 ± 233.2 | 285.2 ± 255.6 |
| CD4-All Doubles, Month 36 | 827.3 ± 922.9 | 969.7 ± 1034.9 | 896.3 ± 770.4 | 239.7 ± 181.7 | 229.7 ± 217.1 |
Among other activation markers expressed were interleukin-2 \[IL-2\] or tumour necrosis factor-alpha \[TNF-α\] or cluster of differentiation 40-ligand \[CD40-L\]. Analysis of cytokines expression was done by means of in vitro flow cytometry using intracellular cytokine staining (ICS). Month 12, 24 and 36 CMI analyses on CD8+ T cells were not performed as no detectable CD8 T+ cell response was measured to any of the vaccine formulations in the primary (108494) study.
| T-cells/million cells | GSK1437173A _LD Group | GSK1437173A _MD Group | GSK1437173A _HD Group | Placebo + GSK1437173A _HD Group | GSK1437173A_MODIFIED Group |
|---|---|---|---|---|---|
| Month 12 | 659.9 ± 594.3 | 767.8 ± 895.1 | 718.9 ± 634.2 | 235.5 ± 244.7 | 176.8 ± 152.7 |
| Month 24 | 541.9 ± 503.1 | 668.9 ± 1140.6 | 543.6 ± 554.7 | 157.0 ± 183.4 | 181.2 ± 158.4 |
| Month 36 | 491.8 ± 604.1 | 583.3 ± 819.0 | 492.3 ± 437.0 | 172.2 ± 155.1 | 162.0 ± 151.4 |
Among other activation markers expressed were interferon-gamma \[IFN-γ\] or tumour necrosis factor-alpha \[TNF-α\] or cluster of differentiation 40-ligand \[CD40-L\]. Analysis of cytokines expression was done by means of in vitro flow cytometry using intracellular cytokine staining (ICS). Month 12, 24 and 36 CMI analyses on CD8+ T cells were not performed as no detectable CD8 T+ cell response was measured to any of the vaccine formulations in the primary (108494) study.
| T-cells/million cells | GSK1437173A _LD Group | GSK1437173A _MD Group | GSK1437173A _HD Group | Placebo + GSK1437173A _HD Group | GSK1437173A_MODIFIED Group |
|---|---|---|---|---|---|
| Month 12 | 1056.2 ± 901.0 | 1164.7 ± 1029.1 | 1168.3 ± 935.4 | 291.7 ± 266.6 | 243.9 ± 204.8 |
| Month 24 | 943.0 ± 809.5 | 1100.2 ± 1158.9 | 1007.8 ± 909.5 | 213.0 ± 207.4 | 233.0 ± 244.5 |
| Month 36 | 768.9 ± 871.5 | 890.2 ± 883.3 | 834.7 ± 743.9 | 205.8 ± 154.5 | 213.9 ± 202.2 |
Among other activation markers expressed were interleukin-2 \[IL-2\] or interferon-gamma \[IFN-γ\] or cluster of differentiation 40-ligand \[CD40-L\]. Analysis of cytokines expression was done by means of in vitro flow cytometry using intracellular cytokine staining (ICS). Month 12, 24 and 36 CMI analyses on CD8+ T cells were not performed as no detectable CD8 T+ cell response was measured to any of the vaccine formulations in the primary (108494) study.
| T-cells/million cells | GSK1437173A _LD Group | GSK1437173A _MD Group | GSK1437173A _HD Group | Placebo + GSK1437173A _HD Group | GSK1437173A_MODIFIED Group |
|---|---|---|---|---|---|
| Month 12 | 673.7 ± 616.0 | 736.2 ± 878.5 | 736.7 ± 660.7 | 193.2 ± 239.4 | 136.0 ± 132.8 |
| Month 24 | 567.9 ± 527.7 | 663.1 ± 1097.0 | 591.5 ± 586.6 | 144.1 ± 196.1 | 133.0 ± 158.1 |
| Month 36 | 497.4 ± 652.5 | 567.9 ± 808.4 | 510.7 ± 522.1 | 117.9 ± 151.7 | 98.1 ± 116.0 |
Among other activation markers expressed were interleukin-2 \[IL-2\] or interferon-gamma \[IFN-γ\] or tumour necrosis factor-alpha \[TNF-α\] . Analysis of cytokines expression was done by means of in vitro flow cytometry using intracellular cytokine staining (ICS). Month 12, 24 and 36 CMI analyses on CD8+ T cells were not performed as no detectable CD8 T+ cell response was measured to any of the vaccine formulations in the primary (108494) study.
| T-cells/million cells | GSK1437173A _LD Group | GSK1437173A _MD Group | GSK1437173A _HD Group | Placebo + GSK1437173A _HD Group | GSK1437173A_MODIFIED Group |
|---|---|---|---|---|---|
| Month 12 | 969.0 ± 811.8 | 1057.2 ± 943.4 | 1062.8 ± 850.3 | 267.5 ± 246.0 | 221.0 ± 180.9 |
| Month 24 | 935.2 ± 801.5 | 1079.9 ± 1040.1 | 981.6 ± 890.9 | 210.8 ± 187.2 | 270.3 ± 248.6 |
| Month 36 | 753.0 ± 852.9 | 912.9 ± 1009.2 | 823.0 ± 727.9 | 202.5 ± 166.3 | 202.8 ± 187.1 |
Concentrations were presented as geometric mean concentrations (GMCs) and expressed in enzyme-linked immunosorbent assay (ELISA) units per milliliter (EL.U/mL).
| EL.U/mL | GSK1437173A _LD Group | GSK1437173A _MD Group | GSK1437173A _HD Group | Placebo + GSK1437173A _HD Group | GSK1437173A_MODIFIED Group |
|---|---|---|---|---|---|
| Anti-gE, Month 12 | 3384.8 (2987.2 to 3835.4) | 4280.3 (3818.4 to 4798.0) | 5258.2 (4725.2 to 5851.3) | 1664.5 (1443.7 to 1919.1) | 1888.2 (1452.7 to 2454.1) |
| Anti-gE, Month 24 | 2363.8 (2081.0 to 2685.0) | 2784.6 (2494.0 to 3109.1) | 3390.0 (3013.6 to 3813.5) | 1126.3 (982.2 to 1291.6) | 1339.1 (1038.3 to 1727.0) |
| Anti-gE, Month 36 | 2064.1 (1834.6 to 2322.3) | 2444.3 (2175.2 to 2746.8) | 2956.4 (2653.6 to 3293.7) | 959.5 (831.0 to 1107.9) | 973.9 (755.4 to 1255.6) |
Concentrations were presented as geometric mean concentrations (GMCs) and expressed in milli-international units per milliliter (mIU/mL).
| mIU/mL | GSK1437173A _LD Group | GSK1437173A _MD Group | GSK1437173A _HD Group | Placebo + GSK1437173A _HD Group | GSK1437173A_MODIFIED Group |
|---|---|---|---|---|---|
| Anti-VZV, Month 12 | 4190.1 (3845.4 to 4565.8) | 4761.3 (4367.0 to 5191.3) | 5559.1 (5141.5 to 6010.7) | 2704.1 (2424.5 to 3016.0) | 2733.8 (2208.8 to 3383.7) |
| Anti-VZV, Month 24 | 2557.4 (2397.5 to 2727.8) | 2673.6 (2523.8 to 2832.3) | 2976.0 (2819.5 to 3141.3) | 1849.3 (1701.8 to 2009.5) | 1922.6 (1643.1 to 2249.6) |
| Anti-VZV, Month 36 | 2426.6 (2257.2 to 2608.8) | 2555.0 (2385.8 to 2736.3) | 2826.7 (2648.4 to 3017.0) | 1729.9 (1582.5 to 1891.1) | 1739.9 (1481.0 to 2044.0) |
Memory B cells specific to the gE antigen, as assessed by the enzyme-linked immunosorbent spot (ELISPOT) method, were expressed as a frequency of the specific memory B-cells per million memory B-cells. Results were tabulated for subjects aged 70 years and older.
| B-cells/million cells | GSK1437173A _LD Group | GSK1437173A _MD Group | GSK1437173A _HD Group | Placebo + GSK1437173A _HD Group | GSK1437173A_MODIFIED Group |
|---|---|---|---|---|---|
| Memory B-cells, Day 0 | 336.5 ± 359.5 | 490.4 ± 704.7 | 356.6 ± 348.0 | 332.3 ± 404.9 | 380.6 ± 299.7 |
| Memory B-cells, Month 3 | 5699.3 ± 8166.2 | 5997.1 ± 5034.6 | 9707.5 ± 8787.1 | 1583.7 ± 2266.0 | 1042.2 ± 1139.9 |
Among biochemical and haematological parameters assessed were albumin \[ALB\], alanine aminotransferase \[ALT\], aspartate aminotransferase \[AST\], basophils \[BAS\], calcium \[CAL\], eosinophils \[EOS\], fibrinogen \[FIB\], haematocrit \[HEM\], hemoglobin \[Hgb\], leucocytes \[LEU\], lymphocytes \[LYM\], lactate dehydrogenate \[LDH\], monocytes \[MON\], neutrophils \[NEU\], partial thromboplastin time \[PTPT\], platelets \[PLA\], pro thrombin time \[PTT\], red blood cells \[RBC\], serum creatinine \[SCREA\], total protein \[TP\]. Levels of haematological/biochemical parameters assessed in terms of normal laboratory values were - unknown, below, within and above.
| Participants | GSK1437173A _LD Group | GSK1437173A _MD Group | GSK1437173A _HD Group | Placebo + GSK1437173A _HD Group | GSK1437173A_MODIFIED Group |
|---|---|---|---|---|---|
| ALB, Day 0 — Unknown | 0 | 0 | 0 | 0 | 0 |
| ALB, Day 0 — Below | 13 | 12 | 14 | 12 | 4 |
| ALB, Day 0 — Within | 57 | 64 | 59 | 61 | 19 |
| ALB, Day 0 — Above | 4 | 1 | 2 | 2 | 1 |
| ALB, Month 2 — Unknown | 0 | 0 | 0 | 0 | 0 |
| ALB, Month 2 — Below | 13 | 14 | 11 | 17 | 6 |
| ALB, Month 2 — Within | 57 | 61 | 62 | 55 | 16 |
| ALB, Month 2 — Above | 2 | 2 | 1 | 3 | 0 |
| ALB, Month 3 — Unknown | 0 | 0 | 1 | 0 | 0 |
| ALB, Month 3 — Below | 8 | 12 | 9 | 17 | 4 |
| ALB, Month 3 — Within | 61 | 62 | 61 | 55 | 17 |
| ALB, Month 3 — Above | 1 | 3 | 2 | 3 | 0 |
| ALT, Day 0 — Unknown | 0 | 0 | 0 | 0 | 1 |
| ALT, Day 0 — Below | 1 | 2 | 0 | 1 | 0 |
| ALT, Day 0 — Within | 150 | 151 | 152 | 154 | 50 |
| ALT, Day 0 — Above | 13 | 13 | 12 | 10 | 3 |
| ALT, Month 2 — Unknown | 0 | 0 | 0 | 0 | 0 |
| ALT, Month 2 — Below | 1 | 1 | 0 | 1 | 0 |
| ALT, Month 2 — Within | 152 | 149 | 155 | 150 | 48 |
| ALT, Month 2 — Above | 9 | 14 | 7 | 13 | 3 |
| ALT, Month 3 — Unknown | 0 | 0 | 1 | 0 | 0 |
| ALT, Month 3 — Below | 1 | 2 | 0 | 1 | 0 |
| ALT, Month 3 — Within | 152 | 150 | 154 | 150 | 46 |
| ALT, Month 3 — Above | 7 | 12 | 6 | 13 | 5 |
| AST, Day 0 — Unknown | 0 | 0 | 0 | 0 | 0 |
| AST, Day 0 — Below | 0 | 1 | 1 | 3 | 0 |
| AST, Day 0 — Within | 156 | 154 | 156 | 148 | 51 |
| AST, Day 0 — Above | 8 | 11 | 7 | 14 | 3 |
| AST, Month 2 — Unknown | 0 | 0 | 0 | 0 | 0 |
| AST, Month 2 — Below | 0 | 1 | 0 | 0 | 0 |
| AST, Month 2 — Within | 150 | 151 | 151 | 151 | 51 |
| AST, Month 2 — Above | 12 | 12 | 11 | 13 | 0 |
| AST, Month 3 — Unknown | 0 | 0 | 2 | 0 | 0 |
| AST, Month 3 — Below | 0 | 3 | 0 | 0 | 0 |
| AST, Month 3 — Within | 151 | 146 | 153 | 153 | 48 |
| AST, Month 3 — Above | 9 | 15 | 6 | 11 | 3 |
| BAS, Day 0 — Unknown | 7 | 11 | 5 | 6 | 1 |
| BAS, Day 0 — Below | 0 | 1 | 0 | 0 | 1 |
| BAS, Day 0 — Within | 148 | 147 | 153 | 153 | 50 |
| BAS, Day 0 — Above | 9 | 7 | 6 | 6 | 2 |
| BAS, Month 2 — Unknown | 0 | 0 | 1 | 0 | 0 |
| BAS, Month 2 — Below | 0 | 1 | 1 | 1 | 1 |
| BAS, Month 2 — Within | 153 | 155 | 152 | 154 | 47 |
| BAS, Month 2 — Above | 9 | 8 | 8 | 9 | 3 |
| BAS, Month 3 — Unknown | 0 | 0 | 0 | 0 | 0 |
| BAS, Month 3 — Below | 0 | 0 | 2 | 0 | 1 |
| BAS, Month 3 — Within | 150 | 151 | 147 | 155 | 48 |
| BAS, Month 3 — Above | 10 | 13 | 12 | 9 | 2 |
| CAL, Day 0 — Unknown | 0 | 0 | 0 | 0 | 0 |
| CAL, Day 0 — Below | 3 | 1 | 2 | 3 | 0 |
| CAL, Day 0 — Within | 70 | 76 | 72 | 71 | 23 |
| CAL, Day 0 — Above | 1 | 0 | 1 | 1 | 1 |
| CAL, Month 2 — Unknown | 0 | 0 | 0 | 0 | 0 |
| CAL, Month 2 — Below | 4 | 1 | 5 | 3 | 0 |
| CAL, Month 2 — Within | 68 | 75 | 68 | 71 | 22 |
| CAL, Month 2 — Above | 0 | 1 | 1 | 1 | 0 |
| CAL, Month 3 — Unknown | 0 | 0 | 1 | 0 | 0 |
| CAL, Month 3 — Below | 5 | 1 | 2 | 5 | 0 |
| CAL, Month 3 — Within | 64 | 76 | 70 | 69 | 21 |
| CAL, Month 3 — Above | 1 | 0 | 0 | 1 | 0 |
| EOS, Day 0 — Unknown | 8 | 11 | 5 | 6 | 1 |
| EOS, Day 0 — Below | 13 | 11 | 12 | 10 | 2 |
| EOS, Day 0 — Within | 130 | 127 | 135 | 137 | 47 |
| EOS, Day 0 — Above | 13 | 17 | 12 | 12 | 4 |
| EOS, Month 2 — Unknown | 0 | 0 | 1 | 0 | 0 |
| EOS, Month 2 — Below | 11 | 8 | 15 | 10 | 3 |
| EOS, Month 2 — Within | 140 | 138 | 128 | 142 | 43 |
| EOS, Month 2 — Above | 11 | 18 | 18 | 12 | 5 |
| EOS, Month 3 — Unknown | 1 | 0 | 0 | 0 | 0 |
| EOS, Month 3 — Below | 10 | 9 | 12 | 8 | 2 |
| EOS, Month 3 — Within | 127 | 144 | 126 | 134 | 45 |
| EOS, Month 3 — Above | 22 | 11 | 23 | 22 | 4 |
| FIB, Day 0 — Unknown | 1 | 4 | 4 | 1 | 0 |
| FIB, Day 0 — Below | 0 | 0 | 0 | 0 | 0 |
| FIB, Day 0 — Within | 36 | 34 | 36 | 39 | 10 |
| FIB, Day 0 — Above | 37 | 39 | 35 | 35 | 14 |
| FIB, Month 2 — Unknown | 0 | 1 | 2 | 1 | 0 |
| FIB, Month 2 — Below | 0 | 0 | 0 | 1 | 0 |
| FIB, Month 2 — Within | 40 | 35 | 37 | 35 | 12 |
| FIB, Month 2 — Above | 32 | 41 | 35 | 38 | 10 |
| FIB, Month 3 — Unknown | 0 | 1 | 1 | 0 | 0 |
| FIB, Month 3 — Below | 0 | 0 | 0 | 1 | 0 |
| FIB, Month 3 — Within | 40 | 36 | 40 | 39 | 9 |
| FIB, Month 3 — Above | 30 | 40 | 32 | 35 | 12 |
| HEM, Day 0 — Unknown | 1 | 4 | 0 | 0 | 0 |
| HEM, Day 0 — Below | 21 | 16 | 27 | 20 | 4 |
| HEM, Day 0 — Within | 141 | 143 | 129 | 137 | 50 |
| HEM, Day 0 — Above | 1 | 3 | 8 | 8 | 0 |
| HEM, Month 2 — Unknown | 0 | 0 | 1 | 0 | 0 |
| HEM, Month 2 — Below | 27 | 19 | 25 | 28 | 4 |
| HEM, Month 2 — Within | 133 | 144 | 131 | 132 | 46 |
| HEM, Month 2 — Above | 2 | 1 | 5 | 4 | 1 |
| HEM, Month 3 — Unknown | 0 | 0 | 0 | 1 | 0 |
| HEM, Month 3 — Below | 30 | 23 | 25 | 25 | 6 |
| HEM, Month 3 — Within | 128 | 137 | 134 | 132 | 45 |
| HEM, Month 3 — Above | 2 | 4 | 2 | 6 | 0 |
| HgB, Day 0 — Unknown | 1 | 4 | 0 | 0 | 0 |
| HgB, Day 0 — Below | 23 | 14 | 19 | 22 | 8 |
| HgB, Day 0 — Within | 138 | 142 | 142 | 137 | 46 |
| HgB, Day 0 — Above | 2 | 6 | 3 | 6 | 0 |
| HgB, Month 2 — Unknown | 0 | 0 | 1 | 0 | 0 |
| HgB, Month 2 — Below | 26 | 22 | 26 | 26 | 6 |
| HgB, Month 2 — Within | 134 | 140 | 134 | 134 | 45 |
| HgB, Month 2 — Above | 2 | 2 | 1 | 4 | 0 |
| HgB, Month 3 — Unknown | 0 | 0 | 0 | 1 | 0 |
| HgB, Month 3 — Below | 27 | 21 | 26 | 24 | 7 |
| HgB, Month 3 — Within | 131 | 141 | 133 | 136 | 44 |
| HgB, Month 3 — Above | 2 | 2 | 2 | 3 | 0 |
| LEU, Day 0 — Unknown | 1 | 4 | 0 | 0 | 0 |
| LEU, Day 0 — Below | 3 | 5 | 2 | 6 | 1 |
| LEU, Day 0 — Within | 153 | 147 | 153 | 153 | 52 |
| LEU, Day 0 — Above | 7 | 10 | 9 | 6 | 1 |
| LEU, Month 2 — Unknown | 0 | 0 | 1 | 0 | 0 |
| LEU, Month 2 — Below | 3 | 7 | 3 | 6 | 0 |
| LEU, Month 2 — Within | 152 | 148 | 153 | 147 | 46 |
| LEU, Month 2 — Above | 7 | 9 | 5 | 11 | 5 |
| LEU, Month 3 — Unknown | 0 | 0 | 0 | 0 | 0 |
| LEU, Month 3 — Below | 2 | 8 | 5 | 6 | 0 |
| LEU, Month 3 — Within | 150 | 150 | 149 | 150 | 50 |
| LEU, Month 3 — Above | 8 | 6 | 7 | 8 | 1 |
| LYM, Day 0 — Unknown | 7 | 11 | 5 | 6 | 1 |
| LYM, Day 0 — Below | 18 | 13 | 24 | 17 | 5 |
| LYM, Day 0 — Within | 137 | 140 | 130 | 137 | 44 |
| LYM, Day 0 — Above | 2 | 2 | 5 | 5 | 4 |
| LYM, Month 2 — Unknown | 0 | 0 | 1 | 0 | 0 |
| LYM, Month 2 — Below | 15 | 18 | 23 | 15 | 7 |
| LYM, Month 2 — Within | 144 | 144 | 131 | 147 | 42 |
| LYM, Month 2 — Above | 3 | 2 | 7 | 2 | 2 |
| LYM, Month 3 — Unknown | 0 | 0 | 0 | 0 | 0 |
| LYM, Month 3 — Below | 12 | 8 | 19 | 20 | 7 |
| LYM, Month 3 — Within | 144 | 154 | 138 | 142 | 42 |
| LYM, Month 3 — Above | 4 | 2 | 4 | 2 | 2 |
| LDH, Day 0 — Unknown | 1 | 1 | 0 | 0 | 0 |
| LDH, Day 0 — Below | 0 | 0 | 0 | 0 | 0 |
| LDH, Day 0 — Within | 68 | 68 | 66 | 70 | 24 |
| LDH, Day 0 — Above | 5 | 8 | 9 | 5 | 0 |
| LDH, Month 2 — Unknown | 0 | 0 | 0 | 0 | 0 |
| LDH, Month 2 — Below | 0 | 0 | 0 | 0 | 0 |
| LDH, Month 2 — Within | 64 | 65 | 64 | 70 | 21 |
| LDH, Month 2 — Above | 8 | 12 | 10 | 5 | 1 |
| LDH, Month 3 — Unknown | 0 | 0 | 1 | 0 | 0 |
| LDH, Month 3 — Below | 0 | 0 | 0 | 0 | 0 |
| LDH, Month 3 — Within | 63 | 63 | 66 | 68 | 20 |
| LDH, Month 3 — Above | 7 | 14 | 6 | 7 | 1 |
| MON, Day 0 — Unknown | 7 | 11 | 5 | 6 | 1 |
| MON, Day 0 — Below | 1 | 4 | 1 | 0 | 1 |
| MON, Day 0 — Within | 148 | 142 | 147 | 148 | 49 |
| MON, Day 0 — Above | 8 | 9 | 11 | 11 | 3 |
| MON, Month 2 — Unknown | 0 | 0 | 1 | 0 | 0 |
| MON, Month 2 — Below | 0 | 0 | 2 | 0 | 0 |
| MON, Month 2 — Within | 153 | 155 | 146 | 145 | 48 |
| MON, Month 2 — Above | 9 | 9 | 13 | 19 | 3 |
| MON, Month 3 — Unknown | 0 | 0 | 0 | 0 | 0 |
| MON, Month 3 — Below | 2 | 1 | 1 | 3 | 0 |
| MON, Month 3 — Within | 145 | 151 | 145 | 148 | 49 |
| MON, Month 3 — Above | 13 | 12 | 15 | 13 | 2 |
| NEU, Day 0 — Unknown | 8 | 11 | 5 | 6 | 1 |
| NEU, Day 0 — Below | 3 | 2 | 3 | 3 | 3 |
| NEU, Day 0 — Within | 145 | 141 | 147 | 146 | 48 |
| NEU, Day 0 — Above | 8 | 12 | 9 | 10 | 2 |
| NEU, Month 2 — Unknown | 1 | 0 | 1 | 0 | 0 |
| NEU, Month 2 — Below | 2 | 5 | 4 | 6 | 1 |
| NEU, Month 2 — Within | 150 | 152 | 144 | 151 | 47 |
| NEU, Month 2 — Above | 9 | 7 | 13 | 7 | 3 |
| NEU, Month 3 — Unknown | 1 | 0 | 0 | 0 | 0 |
| NEU, Month 3 — Below | 7 | 3 | 7 | 6 | 2 |
| NEU, Month 3 — Within | 146 | 157 | 145 | 149 | 46 |
| NEU, Month 3 — Above | 6 | 4 | 9 | 9 | 3 |
| PTPT, Day 0 — Unknown | 3 | 4 | 3 | 0 | 0 |
| PTPT, Day 0 — Below | 5 | 2 | 2 | 3 | 0 |
| PTPT, Day 0 — Within | 42 | 42 | 42 | 43 | 11 |
| PTPT, Day 0 — Above | 3 | 7 | 6 | 5 | 5 |
| PTPT, Month 2 — Unknown | 0 | 1 | 3 | 1 | 0 |
| PTPT, Month 2 — Below | 7 | 4 | 6 | 3 | 0 |
| PTPT, Month 2 — Within | 59 | 58 | 57 | 64 | 20 |
| PTPT, Month 2 — Above | 6 | 11 | 6 | 6 | 2 |
| PTPT, Month 3 — Unknown | 0 | 0 | 1 | 0 | 0 |
| PTPT, Month 3 — Below | 4 | 4 | 6 | 5 | 1 |
| PTPT, Month 3 — Within | 62 | 61 | 59 | 62 | 18 |
| PTPT, Month 3 — Above | 4 | 12 | 7 | 8 | 2 |
| PLA, Day 0 — Unknown | 1 | 4 | 0 | 0 | 0 |
| PLA, Day 0 — Below | 6 | 4 | 9 | 10 | 2 |
| PLA, Day 0 — Within | 147 | 150 | 149 | 148 | 49 |
| PLA, Day 0 — Above | 10 | 8 | 6 | 7 | 3 |
| PLA, Month 2 — Unknown | 0 | 0 | 1 | 0 | 0 |
| PLA, Month 2 — Below | 6 | 7 | 11 | 12 | 1 |
| PLA, Month 2 — Within | 150 | 152 | 145 | 145 | 49 |
| PLA, Month 2 — Above | 6 | 5 | 5 | 7 | 1 |
| PLA, Month 3 — Unknown | 0 | 0 | 0 | 1 | 0 |
| PLA, Month 3 — Below | 6 | 6 | 9 | 12 | 3 |
| PLA, Month 3 — Within | 149 | 153 | 147 | 148 | 46 |
| PLA, Month 3 — Above | 5 | 5 | 5 | 3 | 2 |
| PTT, Day 0 — Unknown | 3 | 3 | 3 | 0 | 0 |
| PTT, Day 0 — Below | 4 | 9 | 5 | 5 | 5 |
| PTT, Day 0 — Within | 44 | 38 | 42 | 44 | 11 |
| PTT, Day 0 — Above | 2 | 5 | 3 | 2 | 0 |
| PTT, Month 2 — Unknown | 0 | 1 | 3 | 1 | 0 |
| PTT, Month 2 — Below | 5 | 10 | 6 | 7 | 3 |
| PTT, Month 2 — Within | 65 | 62 | 61 | 65 | 19 |
| PTT, Month 2 — Above | 2 | 1 | 2 | 1 | 0 |
| PTT, Month 3 — Unknown | 0 | 0 | 1 | 0 | 0 |
| PTT, Month 3 — Below | 5 | 10 | 6 | 8 | 2 |
| PTT, Month 3 — Within | 62 | 64 | 63 | 64 | 19 |
| PTT, Month 3 — Above | 3 | 3 | 3 | 3 | 0 |
| RBC, Day 0 — Unknown | 1 | 5 | 2 | 1 | 0 |
| RBC, Day 0 — Below | 23 | 21 | 25 | 23 | 9 |
| RBC, Day 0 — Within | 137 | 135 | 128 | 136 | 42 |
| RBC, Day 0 — Above | 3 | 5 | 9 | 5 | 3 |
| RBC, Month 2 — Unknown | 0 | 1 | 1 | 0 | 0 |
| RBC, Month 2 — Below | 25 | 23 | 27 | 24 | 8 |
| RBC, Month 2 — Within | 136 | 138 | 128 | 135 | 42 |
| RBC, Month 2 — Above | 1 | 2 | 6 | 5 | 1 |
| RBC, Month 3 — Unknown | 1 | 0 | 0 | 1 | 0 |
| RBC, Month 3 — Below | 27 | 23 | 26 | 23 | 5 |
| RBC, Month 3 — Within | 129 | 138 | 131 | 136 | 46 |
| RBC, Month 3 — Above | 3 | 3 | 4 | 4 | 0 |
| SCREA, Day 0 — Unknown | 1 | 1 | 1 | 0 | 0 |
| SCREA, Day 0 — Below | 4 | 2 | 3 | 3 | 0 |
| SCREA, Day 0 — Within | 130 | 132 | 128 | 135 | 43 |
| SCREA, Day 0 — Above | 29 | 31 | 32 | 27 | 11 |
| SCREA, Month 2 — Unknown | 0 | 0 | 0 | 0 | 0 |
| SCREA, Month 2 — Below | 3 | 2 | 1 | 3 | 2 |
| SCREA, Month 2 — Within | 135 | 131 | 129 | 131 | 38 |
| SCREA, Month 2 — Above | 24 | 31 | 32 | 30 | 11 |
| SCREA, Month 3 — Unknown | 0 | 0 | 1 | 0 | 0 |
| SCREA, Month 3 — Below | 3 | 3 | 2 | 2 | 0 |
| SCREA, Month 3 — Within | 132 | 127 | 130 | 134 | 42 |
| SCREA, Month 3 — Above | 25 | 34 | 28 | 28 | 9 |
| TP, Day 0 — Unknown | 0 | 0 | 0 | 0 | 0 |
| TP, Day 0 — Below | 6 | 2 | 9 | 3 | 1 |
| TP, Day 0 — Within | 68 | 75 | 66 | 72 | 23 |
| TP, Day 0 — Above | 0 | 0 | 0 | 0 | 0 |
| TP, Month 2 — Unknown | 0 | 0 | 0 | 0 | 0 |
| TP, Month 2 — Below | 6 | 2 | 9 | 4 | 2 |
| TP, Month 2 — Within | 66 | 75 | 65 | 71 | 20 |
| TP, Month 2 — Above | 0 | 0 | 0 | 0 | 0 |
| TP, Month 3 — Unknown | 0 | 0 | 1 | 0 | 0 |
| TP, Month 3 — Below | 3 | 7 | 13 | 6 | 0 |
| TP, Month 3 — Within | 67 | 70 | 58 | 69 | 21 |
| TP, Month 3 — Above | 0 | 0 | 1 | 0 | 0 |
Among biochemical and haematological parameters assessed were albumin \[ALB\], calcium \[CAL\], fibrinogen \[FIB\], lactate dehydrogenase \[LDH\], partial thrombo-plastin time \[PTPT\], pro thrombin time \[PTT\], total protein \[TP\]. Levels of haematological/biochemical parameters assessed in terms of normal laboratory values were - below, within, above and missing, as compared to the pre-vaccination status (below, within, above or missing). Values for electrophoresis (globulins and albumin/globulin ratio) were not displayed.
| Participants | GSK1437173A _LD Group | GSK1437173A _MD Group | GSK1437173A _HD Group | Placebo + GSK1437173A _HD Group | GSK1437173A_MODIFIED Group |
|---|---|---|---|---|---|
| ALB - Below — Below | 8 | 7 | 10 | 7 | 2 |
| ALB - Below — Within | 0 | 0 | 0 | 0 | 0 |
| ALB - Below — Above | 0 | 0 | 0 | 0 | 0 |
| ALB - Below — Missing | 0 | 0 | 0 | 0 | 0 |
| ALB - Within — Below | 3 | 5 | 2 | 4 | 2 |
| ALB - Within — Within | 12 | 12 | 12 | 12 | 4 |
| ALB - Within — Above | 0 | 0 | 0 | 0 | 0 |
| ALB - Within — Missing | 1 | 0 | 0 | 1 | 0 |
| CAL - Below — Below | 1 | 1 | — | — | — |
| CAL - Below — Within | 1 | 0 | — | — | — |
| CAL - Below — Above | 0 | 0 | — | — | — |
| CAL - Below — Missing | 0 | 0 | — | — | — |
| CAL - Within — Below | 1 | 0 | 1 | 0 | 0 |
| CAL - Within — Within | 19 | 23 | 21 | 22 | 8 |
| CAL - Within — Above | 0 | 0 | 2 | 1 | 0 |
| CAL - Within — Missing | 1 | 0 | 0 | 1 | 0 |
| CAL - Above — Below | 0 | — | — | — | — |
| CAL - Above — Within | 1 | — | — | — | — |
| CAL - Above — Above | 0 | — | — | — | — |
| CAL - Above — Missing | 0 | — | — | — | — |
| FIB - Within — Below | 0 | 0 | 0 | 0 | 0 |
| FIB - Within — Within | 9 | 5 | 8 | 13 | 4 |
| FIB - Within — Above | 6 | 8 | 4 | 3 | 1 |
| FIB - Within — Missing | 0 | 0 | 0 | 0 | 0 |
| FIB - Above — Below | 0 | 0 | 0 | 0 | 0 |
| FIB - Above — Within | 0 | 0 | 2 | 3 | 0 |
| FIB - Above — Above | 8 | 11 | 10 | 4 | 3 |
| FIB - Above — Missing | 1 | 0 | 0 | 1 | 0 |
| LDH- Within — Below | 0 | 0 | 0 | 0 | 0 |
| LDH- Within — Within | 18 | 19 | 19 | 22 | 8 |
| LDH- Within — Above | 2 | 0 | 1 | 0 | 0 |
| LDH- Within — Missing | 1 | 0 | 0 | 1 | 0 |
| LDH- Above — Below | 0 | 0 | 0 | 0 | — |
| LDH- Above — Within | 1 | 3 | 1 | 1 | — |
| LDH- Above — Above | 1 | 2 | 3 | 0 | — |
| LDH- Above — Missing | 0 | 0 | 0 | 0 | — |
| LDH- Missing — Below | 0 | — | — | — | — |
| LDH- Missing — Within | 0 | — | — | — | — |
| LDH- Missing — Above | 1 | — | — | — | — |
| LDH- Missing — Missing | 0 | — | — | — | — |
| PTPT - Missing — Below | 0 | 0 | 0 | 0 | 0 |
| PTPT - Missing — Within | 0 | 0 | 0 | 0 | 0 |
| PTPT - Missing — Above | 0 | 0 | 0 | 0 | 0 |
| PTPT - Missing — Missing | 22 | 24 | 23 | 24 | 8 |
| PTT - Missing — Below | 0 | 0 | 0 | 0 | 0 |
| PTT - Missing — Within | 0 | 0 | 0 | 0 | 0 |
| PTT - Missing — Above | 0 | 0 | 1 | 0 | 0 |
| PTT - Missing — Missing | 22 | 24 | 22 | 24 | 8 |
| TP - Below — Below | 0 | — | 0 | — | — |
| TP - Below — Within | 2 | — | 1 | — | — |
| TP - Below — Above | 0 | — | 0 | — | — |
| TP - Below — Missing | 0 | — | 0 | — | — |
| TP - Within — Below | 0 | 0 | 2 | 1 | 0 |
| TP - Within — Within | 21 | 24 | 21 | 22 | 8 |
| TP - Within — Above | 0 | 0 | 0 | 0 | 0 |
| TP - Within — Missing | 1 | 0 | 0 | 1 | 0 |
Among biochemical and haematological parameters assessed were albumin \[ALB\], calcium \[CAL\], fibrinogen \[FIB\], lactate dehydrogenase \[LDH\], partial thrombo-plastin time \[PTPT\], pro thrombin time \[PTT\], total protein \[TP\]. Levels of haematological/biochemical parameters assessed in terms of normal laboratory values were - below, within, above and missing, as compared to the pre-vaccination status (below, within, above or missing). Values for electrophoresis (globulins and albumin/globulin ratio) were not displayed.
| Participants | GSK1437173A _LD Group | GSK1437173A _MD Group | GSK1437173A _HD Group | Placebo + GSK1437173A _HD Group | GSK1437173A_MODIFIED Group |
|---|---|---|---|---|---|
| ALB - Below — Below | 4 | 6 | 8 | 6 | 2 |
| ALB - Below — Within | 1 | 1 | 1 | 0 | 0 |
| ALB - Below — Above | 0 | 0 | 0 | 0 | 0 |
| ALB - Below — Missing | 3 | 0 | 1 | 1 | 0 |
| ALB - Within — Below | 2 | 2 | 2 | 4 | 1 |
| ALB - Within — Within | 12 | 15 | 11 | 12 | 5 |
| ALB - Within — Above | 0 | 0 | 0 | 0 | 0 |
| ALB - Within — Missing | 2 | 0 | 1 | 1 | 0 |
| CAL - Below — Below | 1 | 0 | — | — | — |
| CAL - Below — Within | 0 | 1 | — | — | — |
| CAL - Below — Above | 0 | 0 | — | — | — |
| CAL - Below — Missing | 1 | 0 | — | — | — |
| CAL - Within — Below | 0 | 0 | 2 | 0 | 0 |
| CAL - Within — Within | 16 | 23 | 20 | 22 | 8 |
| CAL - Within — Above | 1 | 0 | 0 | 0 | 0 |
| CAL - Within — Missing | 4 | 0 | 2 | 2 | 0 |
| CAL - Above — Below | 0 | — | — | — | — |
| CAL - Above — Within | 1 | — | — | — | — |
| CAL - Above — Above | 0 | — | — | — | — |
| CAL - Above — Missing | 0 | — | — | — | — |
| FIB - Within — Below | 0 | 0 | 0 | 0 | 0 |
| FIB - Within — Within | 8 | 8 | 6 | 11 | 4 |
| FIB - Within — Above | 5 | 5 | 5 | 3 | 1 |
| FIB - Within — Missing | 2 | 0 | 1 | 2 | 0 |
| FIB - Above — Below | 0 | 0 | 0 | 0 | 0 |
| FIB - Above — Within | 0 | 1 | 3 | 1 | 0 |
| FIB - Above — Above | 6 | 10 | 8 | 7 | 3 |
| FIB - Above — Missing | 3 | 0 | 1 | 0 | 0 |
| LDH - Within — Below | 0 | 0 | 0 | 0 | 0 |
| LDH - Within — Within | 14 | 16 | 15 | 20 | 8 |
| LDH - Within — Above | 2 | 3 | 3 | 1 | 0 |
| LDH - Within — Missing | 5 | 0 | 2 | 2 | 0 |
| LDH - Above — Below | 0 | 0 | 0 | 0 | — |
| LDH - Above — Within | 0 | 4 | 1 | 1 | — |
| LDH - Above — Above | 2 | 1 | 3 | 0 | — |
| LDH - Above — Missing | 0 | 0 | 0 | 0 | — |
| LDH - Missing — Below | 0 | — | — | — | — |
| LDH - Missing — Within | 1 | — | — | — | — |
| LDH - Missing — Above | 0 | — | — | — | — |
| LDH - Missing — Missing | 0 | — | — | — | — |
| PTPT - Missing — Below | 0 | 1 | 2 | 1 | 0 |
| PTPT - Missing — Within | 18 | 22 | 20 | 19 | 8 |
| PTPT - Missing — Above | 1 | 1 | 0 | 2 | 0 |
| PTPT - Missing — Missing | 3 | 0 | 1 | 2 | 0 |
| PTT - Missing — Below | 1 | 1 | 0 | 2 | 0 |
| PTT - Missing — Within | 18 | 23 | 22 | 20 | 8 |
| PTT - Missing — Above | 0 | 0 | 0 | 0 | 0 |
| PTT - Missing — Missing | 3 | 0 | 1 | 2 | 0 |
| TP - Below — Below | 0 | — | 0 | — | — |
| TP - Below — Within | 0 | — | 1 | — | — |
| TP - Below — Above | 0 | — | 0 | — | — |
| TP - Below — Missing | 2 | — | 0 | — | — |
| TP - Within — Below | 0 | 0 | 2 | 2 | 0 |
| TP - Within — Within | 19 | 24 | 19 | 20 | 8 |
| TP - Within — Above | 0 | 0 | 0 | 0 | 0 |
| TP - Within — Missing | 3 | 0 | 2 | 2 | 0 |
Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 pain = pain that prevented normal activity. Grade 3 redness/swelling = redness/swelling spreading beyond 100 millimeters (mm) of injection site.
| Participants | GSK1437173A _LD Group | GSK1437173A _MD Group | GSK1437173A _HD Group | Placebo + GSK1437173A _HD Group | GSK1437173A_MODIFIED Group |
|---|---|---|---|---|---|
| Any Pain, Dose 1 | 94 | 11 | 99 | 2 | 7 |
| Grade 3 Pain, Dose 1 | 0 | 0 | 3 | 0 | 0 |
| Any Redness, Dose 1 | 40 | 49 | 43 | 1 | 2 |
| Grade 3 Redness, Dose 1 | 2 | 2 | 3 | 0 | 0 |
| Any Swelling, Dose 1 | 26 | 21 | 24 | 3 | 1 |
| Grade 3 Swelling, Dose 1 | 1 | 2 | 2 | 0 | 0 |
| Any Pain, Dose 2 | 99 | 93 | 99 | 93 | 4 |
| Grade 3 Pain, Dose 2 | 4 | 3 | 3 | 3 | 0 |
| Any Redness, Dose 2 | 51 | 54 | 52 | 48 | 2 |
| Grade 3 Redness, Dose 2 | 1 | 3 | 2 | 2 | 0 |
| Any Swelling, Dose 2 | 30 | 23 | 30 | 27 | 0 |
| Grade 3 Swelling, Dose 2 | 0 | 0 | 1 | 0 | 0 |
| Any Pain, Across doses | 115 | 12 | 122 | 93 | 9 |
| Grade 3 Pain, Across doses | 4 | 3 | 6 | 3 | 0 |
| Any Redness, Across doses | 68 | 66 | 68 | 49 | 2 |
| Grade 3 Redness, Across doses | 2 | 5 | 4 | 2 | 0 |
| Any Swelling, Across doses | 44 | 33 | 45 | 30 | 1 |
| Grade 3 Swelling, Across doses | 1 | 2 | 2 | 0 | 0 |
Assessed solicited general symptoms were arthralgia, fatigue, fever \[defined as oral temperature equal to or above (≥) 37.5 degrees Celsius (°C)\], headache and myalgia. Any = occurrence of the symptom regardless of intensity grade. Grade 3 symptom = symptom that prevented normal activity. Grade 3 fever = fever \> 39.0 °C. Related = symptom assessed by the investigator as related to the vaccination.
| Participants | GSK1437173A _LD Group | GSK1437173A _MD Group | GSK1437173A _HD Group | Placebo + GSK1437173A _HD Group | GSK1437173A_MODIFIED Group |
|---|---|---|---|---|---|
| Any Fatigue, Dose 1 | 36 | 48 | 46 | 20 | 8 |
| Grade 3 Fatigue, Dose 1 | 1 | 2 | 2 | 2 | 1 |
| Related Fatigue, Dose 1 | 30 | 34 | 34 | 12 | 6 |
| Any Fever, Dose 1 | 7 | 7 | 5 | 4 | 0 |
| Grade 3 Fever, Dose 1 | 0 | 0 | 0 | 0 | 0 |
| Related Fever, Dose 1 | 7 | 5 | 3 | 4 | 0 |
| Any Headache, Dose 1 | 23 | 25 | 24 | 13 | 7 |
| Grade 3 Headache, Dose 1 | 0 | 0 | 2 | 0 | 0 |
| Related Headache, Dose 1 | 19 | 17 | 13 | 6 | 6 |
| Any Myalgia, Dose 1 | 48 | 57 | 46 | 11 | 8 |
| Grade 3 Myalgia, Dose 1 | 1 | 2 | 2 | 1 | 0 |
| Related Myalgia, Dose 1 | 41 | 52 | 41 | 10 | 6 |
| Any Fatigue, Dose 2 | 56 | 70 | 52 | 38 | 9 |
| Grade 3 Fatigue, Dose 2 | 2 | 6 | 4 | 1 | 0 |
| Related Fatigue, Dose 2 | 47 | 48 | 43 | 27 | 7 |
| Any Fever, Dose 2 | 13 | 13 | 18 | 5 | 0 |
| Grade 3 Fever, Dose 2 | 0 | 1 | 0 | 0 | 0 |
| Related Fever, Dose 2 | 12 | 12 | 18 | 5 | 0 |
| Any Headache, Dose 2 | 39 | 47 | 39 | 27 | 7 |
| Grade 3 Headache, Dose 2 | 2 | 3 | 2 | 0 | 0 |
| Related Headache, Dose 2 | 32 | 32 | 35 | 21 | 5 |
| Any Myalgia, Dose 2 | 59 | 71 | 59 | 46 | 5 |
| Grade 3 Myalgia, Dose 2 | 4 | 7 | 4 | 2 | 0 |
| Related Myalgia, Dose 2 | 52 | 61 | 57 | 41 | 4 |
| Any Fatigue, Across doses | 69 | 85 | 73 | 47 | 1 |
| Grade 3 Fatigue, Across doses | 3 | 7 | 6 | 3 | 1 |
| Related Fatigue, Across doses | 57 | 60 | 59 | 33 | 9 |
| Any Fever, Across doses | 19 | 18 | 22 | 9 | 0 |
| Grade 3 Fever, Across doses | 0 | 1 | 0 | 0 | 0 |
| Related Fever, Across doses | 18 | 15 | 20 | 9 | 0 |
| Any Headache, Across doses | 47 | 59 | 51 | 36 | 9 |
| Grade 3 Headache, Across doses | 2 | 3 | 4 | 0 | 0 |
| Related Headache, Across doses | 39 | 41 | 42 | 25 | 7 |
| Any Myalgia, Across doses | 74 | 89 | 70 | 49 | 9 |
| Grade 3 Myalgia, Across doses | 5 | 8 | 6 | 3 | 0 |
| Related Myalgia, Across doses | 66 | 80 | 67 | 46 | 7 |
Clinically diagnosed episodes included rash that was assessed by hives, idiopathic thrombocytopenic purpura, petechiae.
| Participants | GSK1437173A _LD Group | GSK1437173A _MD Group | GSK1437173A _HD Group | Placebo + GSK1437173A _HD Group | GSK1437173A_MODIFIED Group |
|---|---|---|---|---|---|
| Number of Subjects With Occurrence of Clinically Diagnosed Herpes Zoster (HZ) Episodes | 1 | 0 | 0 | 0 | 0 |
Clinically diagnosed episodes included rash that was assessed by hives, idiopathic thrombocytopenic purpura, petechiae.
| Participants | GSK1437173A _LD Group | GSK1437173A _MD Group | GSK1437173A _HD Group | Placebo + GSK1437173A _HD Group | GSK1437173A_MODIFIED Group |
|---|---|---|---|---|---|
| Month 3 - Month 12 | 0 | 0 | 0 | 1 | 0 |
| Month 12 - Month 24 | 1 | 0 | 0 | 0 | 0 |
| Month 24 - Month 36 | 0 | 0 | 0 | 0 | 1 |
An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. Grade 3 AE = an AE which prevented normal, everyday activities. Related = AE assessed by the investigator as related to the vaccination.
| Participants | GSK1437173A _LD Group | GSK1437173A _MD Group | GSK1437173A _HD Group | Placebo + GSK1437173A _HD Group | GSK1437173A_MODIFIED Group |
|---|---|---|---|---|---|
| Any AE(s) | 55 | 52 | 54 | 41 | 16 |
| Grade 3 AE(s) | 7 | 10 | 10 | 5 | 4 |
| Related AE(s) | 20 | 22 | 24 | 13 | 2 |
Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.
| Participants | GSK1437173A _LD Group | GSK1437173A _MD Group | GSK1437173A _HD Group | Placebo + GSK1437173A _HD Group | GSK1437173A_MODIFIED Group |
|---|---|---|---|---|---|
| Number of Subjects With Serious Adverse Events (SAEs) | 2 | 4 | 3 | 6 | 3 |
Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.
| Participants | GSK1437173A _LD Group | GSK1437173A _MD Group | GSK1437173A _HD Group | Placebo + GSK1437173A _HD Group | GSK1437173A_MODIFIED Group |
|---|---|---|---|---|---|
| Month 3 - Month 12 | 11 | 14 | 11 | 16 | 3 |
| Month 12 - Month 24 | 21 | 27 | 29 | 25 | 11 |
| Month 24 - Month 36 | 19 | 12 | 25 | 20 | 5 |
Collected over Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-vaccination period; SAEs: during the entire study period (from Day 0 to Month 36).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| GSK1437173A _LD Group | 2/164 (1.2%) | 53/164 (32.3%) | 134/164 (81.7%) |
| GSK1437173A _MD Group | 3/166 (1.8%) | 57/166 (34.3%) | 142/166 (85.5%) |
| GSK1437173A _HD Group | 3/165 (1.8%) | 68/165 (41.2%) | 140/165 (84.8%) |
| Placebo + GSK1437173A _HD Group | 5/165 (3%) | 67/165 (40.6%) | 124/165 (75.2%) |
| Placebo Group | 1/54 (1.9%) | 22/54 (40.7%) | 19/54 (35.2%) |
| Event | GSK1437173A _LD Group | GSK1437173A _MD Group | GSK1437173A _HD Group | Placebo + GSK1437173A _HD Group | Placebo Group |
|---|---|---|---|---|---|
| BradyarrhythmiaCardiac disorders | 0/164 | 0/166 | 0/165 | 0/165 | 3/54 |
| Cardiac failureCardiac disorders | 3/164 | 2/166 | 1/165 | 1/165 | 2/54 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 0/164 | 0/166 | 0/165 | 0/165 | 2/54 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 2/164 | 1/166 | 5/165 | 3/165 | 1/54 |
| Angina pectorisCardiac disorders | 0/164 | 2/166 | 4/165 | 3/165 | 0/54 |
| Transient ischaemic attackNervous system disorders | 3/164 | 0/166 | 1/165 | 4/165 | 0/54 |
| Microcytic anaemiaBlood and lymphatic system disorders | 0/164 | 0/166 | 0/165 | 0/165 | 1/54 |
| Acute myocardial infarctionCardiac disorders | 0/164 | 0/166 | 1/165 | 0/165 | 1/54 |
| Atrial fibrillationCardiac disorders | 0/164 | 2/166 | 0/165 | 3/165 | 1/54 |
| Atrial flutterCardiac disorders | 0/164 | 0/166 | 0/165 | 0/165 | 1/54 |
| Event | GSK1437173A _LD Group | GSK1437173A _MD Group | GSK1437173A _HD Group | Placebo + GSK1437173A _HD Group | Placebo Group |
|---|---|---|---|---|---|
| PainGeneral disorders | 115/164 | 121/166 | 122/165 | 93/165 | 9/54 |
| MyalgiaMusculoskeletal and connective tissue disorders | 75/164 | 89/166 | 70/165 | 49/165 | 9/54 |
| FatigueGeneral disorders | 69/164 | 85/166 | 73/165 | 47/165 | 12/54 |
| ErythemaSkin and subcutaneous tissue disorders | 68/164 | 65/166 | 68/165 | 50/165 | 2/54 |
| HeadacheNervous system disorders | 48/164 | 60/166 | 51/165 | 36/165 | 9/54 |
| SwellingGeneral disorders | 43/164 | 32/166 | 45/165 | 30/165 | 1/54 |
| PyrexiaGeneral disorders | 20/164 | 19/166 | 22/165 | 9/165 | 0/54 |
| Age, Continuous(Years) | GSK1437173A _LD Group | GSK1437173A _MD Group | GSK1437173A _HD Group | Placebo + GSK1437173A _HD Group | GSK1437173A_MODIFIED GROUP | Total |
|---|---|---|---|---|---|---|
| Mean | 72.8 ± 5.5 | 72.9 ± 5.1 | 73.0 ± 5.7 | 73.1 ± 5.9 | 72.1 ± 5.2 | 72.9 ± 5.5 |
| Sex: Female, Male(Participants) | GSK1437173A _LD Group | GSK1437173A _MD Group | GSK1437173A _HD Group | Placebo + GSK1437173A _HD Group | GSK1437173A_MODIFIED GROUP | Total |
|---|---|---|---|---|---|---|
| Female | 88 | 100 | 85 | 95 | 36 | 404 |
| Male | 76 | 66 | 80 | 70 | 18 | 310 |
| Race/Ethnicity, Customized(Participants) | GSK1437173A _LD Group | GSK1437173A _MD Group | GSK1437173A _HD Group | Placebo + GSK1437173A _HD Group | GSK1437173A_MODIFIED GROUP | Total |
|---|---|---|---|---|---|---|
| Geographic ancestry — African Heritage/African American | 0 | 1 | 0 | 0 | 0 | 1 |
| Geographic ancestry — Asian - Central/South Asian Heritage | 0 | 1 | 0 | 0 | 0 | 1 |
| Geographic ancestry — White - Arabic/North African Heritage | 1 | 1 | 1 | 0 | 0 | 3 |
| Geographic ancestry — White - Caucasian/European Heritage | 162 | 163 | 164 | 165 | 54 | 708 |
| Geographic ancestry — Other | 1 | 0 | 0 | 0 | 0 | 1 |
Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.
Ran from Feb 2007 to primary completion in Oct 2007, 7 months.
Results were first posted in Jan 2019, 11 years 3 months after primary completion. A results delay was requested in Mar 2012.
Of 22 phase 2 interventional studies under Herpes Zoster, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 27. This study's 7 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.